Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the darbepoetin alfa (aranesp) market size evolved in recent years?

The market for darbepoetin alfa (aranesp) has significantly expanded in the recent past. Its growth is projected to further increase from $5.81 billion in 2024 to $6.11 billion in 2025, with a compound annual growth rate (CAGR) of 5.2%. Factors such as advancements in anemia treatment, the rising demand for erythropoiesis-stimulating agents (ESAs), innovation in the biopharmaceutical sector, clinical acceptance, and better patient outcomes have contributed to the growth during the historic period.

What are the predictions for the darbepoetin alfa (aranesp) market size in the coming years?

Expectations are high for the darbepoetin alfa (aranesp) market to experience robust growth in the coming years. By 2029, it’s estimated the market will have expanded to $7.51 billion, with an expected compound annual growth rate (CAGR) of 5.3%. The anticipated growth within the forecast period can be attributed to factors such as health insurance reimbursement policies, enhancing education and awareness, advancements in healthcare infrastructure, pressing needs in renal care, and the aging population. Key trends to watch for in the forecast period include expanded global market access, integrated digital health solutions, customized treatment plans, incorporation of biosimilars, and longer-lasting formulations.

Get your darbepoetin alfa (aranesp) market report here!

https://www.thebusinessresearchcompany.com/report/darbepoetin-alfa-aranesp-global-market-report

What key factors are fueling the growth of the darbepoetin alfa (aranesp) market?

The proliferation of chronic illnesses is anticipated to fuel the expansion of the darbepoetin alfa market. Chronic diseases, which persist for three months or longer and may worsen over time, are often treated using darbepoetin alfa to counteract anemia induced by cancer chemotherapy. For example, June 2024 data from the Australian Institute of Health and Welfare revealed that in 2022, 171,500, or 90% of all deaths, were due to chronic conditions, equivalent to a rate of 659 per 100,000 population. While the age-adjusted death rate from chronic diseases dipped to 448 per 100,000 in 2020, the rate rose to 459 in 2021, and further to 490 in 2022. Consequently, the escalating incidence of chronic illnesses contributes to the surge in the darbepoetin alfa market.

How is the global darbepoetin alfa (aranesp) market divided into key segments?

The darbepoetin alfa (aranesp) market covered in this report is segmented –

1) By Type: Epogen, Procrit, Aranesp, Other Types

2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

3) By Application: Patients With Chronic Kidney Disease, Patients With Cancer, Other Applications

Subsegments:

1) By Epogen: Standard Formulations, Enhanced Formulations

2) By Procrit: Standard Formulations, Biosimilars

3) By Aranesp: Single-Dose Vials, Multi-Dose Vials

4) By Other Types: Combination Therapies, Alternative Erythropoiesis-Stimulating Agents

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12171&type=smp

Who are the key firms paving the way for growth in the darbepoetin alfa (aranesp) market?

Major companies operating in the darbepoetin alfa (aranesp) market include Johnson & Johnson, Amgen Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., Serum Institute of India Pvt. Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Ltd., Biocon Ltd., Reliance Life Sciences, Torrent Pharmaceuticals Ltd., 3SBio Inc., Cadila Healthcare Ltd., Dong-A ST Co. Ltd., Chong Kun Dang Holdings, Hetero Drugs Ltd., Intas Pharmaceuticals Ltd., Avesthagen Pharma, Stada Arzneimittel AG, Ranbaxy Laboratories Ltd., Sandoz International GmbH, Shandong Kexing Bioproducts Co. Ltd., Kyowa Kirin Co. Ltd., Polifarma S.p.A.

Which trends are expected to transform the darbepoetin alfa (aranesp) market?

In the darbepoetin alfa market, the emergence of product innovations is a pivotal trend gaining traction. In order to maintain their competitiveness, premier companies in this market are leveraging modern technologies. To illustrate, GlaxoSmithKline. Ltd., a UK-based firm in the pharmaceutical and biotechnological sector, unveiled Jesduvroq (daprodustat) in February 2023 with the approval of the US Food and Drug Administration (FDA). This compound, also known as recombinant human erythropoietin (rhEPO, darbepoetin alfa, or epoetin alfa), is a hypoxia-inducible factor prolyl hydroxylase inhibitor that is taken orally and is utilized once daily for treating anemia caused by chronic kidney disease (CKD) in patients who have been undergoing dialysis for no less than four months.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12171

What regions are contributing significantly to the growth of the darbepoetin alfa (aranesp) market?

North America was the largest region in the darbepoetin alfa (Aranesp) market in 2024. The regions covered in the darbepoetin alfa (Aranesp) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Waterless Cosmetics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/waterless-cosmetics-global-market-report

Luxury Bath And Body Products Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/luxury-bath-and-body-products-global-market-report

Face Creams Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/face-creams-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: